Can Exelixis Beat Expectations Again When Analysts Have Already Decided It Will?

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Exelixis typically reports after market close, meaning Day 0 reflects pre-earnings anticipation (the market closes before results drop) and Day +1 captures the first full session where investors react to the actual numbers.

Historical price action shows extreme volatility and directional inconsistency around Exelixis earnings. The average absolute Day 0 move is 1.26% with a range of 3.13%, indicating modest pre-earnings positioning. However, Day +1 moves are far more dramatic: the average absolute move is 9.34% with a range of 7.85%, reflecting sharp post-earnings reactions as investors digest results and guidance.

The direction of Day +1 moves is highly unpredictable. The most recent report (August 5, 2026) saw a +1.25% Day 0 gain followed by a -7.94% Day +1 decline despite the +9.33% EPS beat, suggesting profit-taking or disappointing guidance overshadowed the beat. In contrast, the prior report (May 5, 2026) delivered a +0.57% Day 0 move and a +9.64% Day +1 surge. The largest Day +1 gain in the dataset was +20.84% (May 13, 2025), while the largest decline was -16.78% (July 28, 2025).

Investors should prepare for significant post-earnings volatility — the 9.34% average Day +1 move implies a potential swing of roughly $6 in either direction from the current $66.29 price. Given the stock's proximity to all-time highs and the 65.5% year-to-date gain, downside risk may be elevated if results or guidance disappoint, as profit-taking could accelerate. Conversely, a strong beat with positive pipeline updates could drive another double-digit rally.

Part 3: What Analysts Are Saying

Analysts maintain a cautious stance on Exelixis, with a consensus rating of Hold (3.65 on a 5-point scale) and a mean price target of $55.35 — implying 16.5% downside from the current price of $66.29. The rating breakdown shows 7 Strong Buys, 0 Moderate Buys, 12 Holds, 1 Moderate Sell, and 0 Strong Sells across 20 analysts. The high target estimate of $70.00 suggests +5.6% upside, while the low target of $41.00 implies -38.1% downside, reflecting wide dispersion in views on valuation and growth prospects.

Sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 3.65. This stability suggests analysts are waiting for the Q3 report and updated guidance before adjusting views, particularly given the FDA review extension for zanzalintinib and the stock's recent run to all-time highs. The lack of sentiment improvement despite the 65.5% year-to-date gain indicates the Street believes much of the good news is already priced in.

The consensus price target of $55.35 sits 16.5% below the current price, signaling that analysts see limited upside at current levels unless the company delivers a significant positive surprise or pipeline catalyst. Recent target raises — such as Citizens lifting its target from $55 to $65 — reflect acknowledgment of the stock's momentum, but the broader Street remains cautious. BMO Capital's $54 target and Market Perform rating underscore the view that while the cabozantinib franchise is "durable and cash-generative," valuation constraints limit further appreciation. Investors should interpret the wide target range ($41 to $70) as reflecting uncertainty around pipeline execution, competitive dynamics, and the sustainability of margin expansion.

Part 4: Technical Picture

The Barchart Technical Opinion for Exelixis is 100% Buy, unchanged from last week and last month, indicating sustained bullish momentum heading into earnings. The signal has remained at maximum strength throughout October, reflecting strong technical conviction despite the stock trading near all-time highs.

Timeframe Analysis:

• Short-term (100% Buy): Maximum buy signal indicates powerful near-term momentum, with the stock breaking out to new highs and showing no signs of exhaustion heading into the earnings event.
• Medium-term (100% Buy): Bullish signal across the intermediate timeframe confirms the uptrend is well-established, supported by rising moving averages and consistent buying pressure over the past several weeks.
• Long-term (100% Buy): Strong buy signal in the longer-term timeframe reflects a durable uptrend, with the stock up 65.5% over the past year and trading well above all major moving averages.

The trend is characterized by Top 1% strength and Top 1% directional momentum, placing Exelixis among the most technically robust stocks in its peer group. This elite positioning suggests the stock is in a powerful uptrend with broad-based buying support, though the extreme readings also raise the risk of mean reversion if earnings disappoint.

The stock is trading at $66.29, above all key moving averages: the 5-day ($65.32), 10-day ($64.33), 20-day ($61.72), 50-day ($58.84), 100-day ($56.49), and 200-day ($50.68). This alignment confirms a strong uptrend across all timeframes, with the stock accelerating away from longer-term support levels. The +30.8% gain above the 200-day moving average underscores the magnitude of the rally.

However, the technical setup is cautionary for earnings despite the bullish signals. The stock hit an all-time high of $65.62 on October 28, 2026, and is trading just +1.0% below that level, leaving little room for further upside without a significant positive catalyst. The Top 1% strength and directional readings suggest the trend is extended, and historical earnings volatility (average 9.34% Day +1 move) implies elevated risk of a sharp reversal if results or guidance disappoint. Investors should be prepared for significant post-earnings price action in either direction, with downside risk amplified by the stock's proximity to all-time highs and the 16.5% gap between the current price and the $55.35 analyst consensus target.